TW202203946A - Composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals - Google Patents

Abstract

Provided is a composition or medicine for treating Covid-19, and a medicine for treating chronic or acute virus infection and/or sepsis mainly in humans, said medicine indicating a superior antiviral effect to the antiviral effect of conventionally known DMSO or I2. This composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals contains at least one iodine source selected from the group consisting of iodide salts and povidone-iodine, and at least one sulfur source selected from the group consisting of dimethyl sulfoxide and methylsulfonylmethane.

Description

Composition for the prevention or treatment of chronic or acute viral infections and/or sepsis in humans or animals

The present invention relates to compositions for the prevention or treatment of chronic or acute viral infections and/or sepsis in humans or animals.

Mortality rates from viral infections such as SARS (Severe Acute Respiratory Syndrome), Norovirus, and Avian Influenza virus have been increasing in recent history. Since December 8, 2019, some cases of pneumonia of unknown etiology have been reported in Wuhan, Hubei Province, China (Lu h 2020). The recent epidemic of the coronavirus, later named COVID-19, is becoming a worldwide threat due to its high infectivity and pathogenicity.

The emergence of a new influenza virus has an urgent need for early response. The development of antiviral vaccines is a solution to this problem, but vaccines are only effective in preventing specific viral infections. The research, development and manufacture of vaccines are time-consuming and economical resources necessary, and the risk of failure is high. Considering the rapid spread of new coronaviruses including those that cause COVID-19, improving innate and adaptive antiviral defenses as preventive and therapeutic agents, and on the other hand, effective antiviral agents against many viruses For urgently necessary.

Viral respiratory infections are an important cause of morbidity and mortality in the world. Fisher et al. reveal that the LPO/I ₂ /H ₂ O ₂ oxidative host defense system has potent activity against two major respiratory viral pathogens, adenovirus and RSV. Further, the lactoperoxidase/I ₂ /H ₂ O ₂ system, through the delivery of I ^- to the respiratory mucosa, contributes to the antiviral defense of the respiratory tract, and has the potential to enhance innate antiviral immunity (non-patented). Reference 1). This study suggests that activation of the lactoperoxidase/I ₂ /H ₂ O ₂ system by the use of iodide compounds may contribute to the antiviral defense of the respiratory tract, enhancing innate antiviral defenses through the delivery of I ^- to the respiratory mucosa. Possibility of virus immunity.

Zinc (Zn) is an important trace element that plays an important role in the initiation and maintenance of a strong immune response. Further, Zn is very important for compounds including human rhinovirus (Korant and Butterworth, 1976, Geist et al., 1987), herpes simplex virus (Kuempel, Arens and Travis, 2000), human immunodeficiency virus (Haraguchi et al., 1999), Hepatitis C virus (Yuasa et al., 2006), respiratory syncytial virus [RS virus] (Suara and Crowe, 2004), vaccinia virus (Katz and Margalith, 1981), picornavirus (Krenn, B et al. 2009), coronaviruses and adenoviruses (Te Velthuiis AJ et al. 2010), and various viruses of porcine coronavirus (Wei, Z, M et al. 2012) showed direct blocking effects.

Dimethyl sulfoxide (DMSO) is a completely natural substance derived from wood pulp. In 1963, it was discovered that this compound can penetrate the skin or other membranes without causing damage, and can deliver components to living systems. DMSO easily induces oxidative stress and increases oxygen levels, which can act as an antiviral agent. This compound was shown to correct the sepsis state associated with the underregulation of immune inflammatory response induced by viral infection (non-patent literature). Mechanistically, DMSO is a powerful antioxidant that regulates the activation of transcription factors in septic animals and can function as a carrier for other drugs. There is a long history of safe use of DMSO in the clinical field. [Prior Art Literature] [Non-patent literature]

[Non-Patent Document 1] Fischer, AJ, NJ Lennemann, S. Krishnamurthy, P. Pocza, L. Durairaj, JL Launspach, BA Rhein, C. Wohlford-Lenane, D. Lorentzen and B. Banfi (2011). "Enhancement of respiratory mucosal antiviral defenses by the oxidation of iodide." American journal of respiratory cell and molecular biology 45 (4):874-881. [Non-Patent Literature 2] Houston, DM, JJ Bugert, SP Denyer and CM Heard (2017) . "Potentiated virucidal activity of pomegranate rind extract (PRE) and punicalagin against Herpes simplex virus (HSV) when co-administered with zinc (II) ions, and antiviral activity of PRE against HSV and aciclovir-resistant HSV." PloS one 12 ( 6). [Non-Patent Document 3] Huang, S.-H., C.-H. Wu, S.-J. Chen, H.-K. Sytwu and G.-J. Lin (2020). "Immunomodulatory effects and potential clinical applications of dimethyl sulfoxide." Immunobiology: 151906. [Non-Patent Document 4] Iwata, A., ML Morrison and MB Roth (2014). "Iodide protects heart tissue from reperfusion injury." PloS one 9 (11) . [Non-Patent Document 5] Krenn, B., E. Gaudernak, B. Holzer, K. Lanke, F. Van Kuppeveld and J. Seipelt (2009). "Antiviral activity of the zinc ionophores pyrithione and hinokitiol against picornavirus infections." Journal of virology 83 (1):58-64. [Non-Patent Literature 6] Read, SA, S. Obeid, C. Ahlenstiel and G. Ahlenstiel (2019). "The role of zinc in antiviral immunity." Advances in Nutrition 10 (4): 696-710. [Non-Patent Literature 7] Te Velthuis, AJ, SH van den Worm, AC Sims, RS Baric, EJ Snijder and MJ van Hemert (2010). "Zn ²⁺ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture." PLoS pathogens 6 (11). [ Non-Patent Document 8] Wei, Z., M. Burwinkel, C. Palissa, E. Ephraim and MF Schmidt (2012). "Antiviral activity of zinc salts against transmissible gastroenteritis virus in vitro." Veterinary microbiology 160 (3-4) : 468-472. [Non-Patent Document 9] Chang, CK, MV Albarillo and W. Schumer (2001). "Therapeutic effect of dimethyl sulfoxide on ICAM-1 gene expression and activation of NF-κB and AP-1 in septic rats ." Journal of Surgical R esearch 95 (2): 181-187. [Non-Patent Document 10] Chang, CK, S. Llanes and W. Schumer (1999). "Inhibitory effect of dimethyl sulfoxide on nuclear factor-κB activation and intercellular adhesion molecule 1 gene expression in septic rats." Journal of Surgical Research 82 (2): 294-299. [Non-Patent Literature 11] Guo, Q., Q. Wu, D. Bai, Y. Liu, L. Chen, S. Jin, Y . Wu and K. Duan (2016). "Potential use of dimethyl sulfoxide in treatment of infections caused by Pseudomonas aeruginosa." Antimicrobial agents and chemotherapy 60 (12): 7159-7169. [Non-Patent Literature 12] Macdonald, J., HF Galley and NR Webster (2003). "Oxidative stress and gene expression in sepsis." British journal of anaesthesia 90 (2): 221-232. [Non-Patent Literature 13] Han, B. and BX Hoang (2018). Metal complexes as pharmaceuticals for treatment and prevention of cancer and inflammatory diseases, Google Patents. [Non-Patent Literature 14] Hoang, BX, B. Han, HX Nguyen and KT Dang (2018). "Nutritional Supplement “Bao Khi Khang” as an Adjuvant Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Dis ease." Journal of medicinal food 21 (10): 1053-1059. [Non-Patent Literature 15] Hoang, BX, B. Han, DG Shaw and M. Nimni (2016). "Zinc as a possible preventive and therapeutic agent in pancreatic, prostate, and breast cancer." European Journal of Cancer Prevention 25 (5): 457-461. [Non-Patent Literature 16] Hoang, BX, BT Le, HD Tran, C. Hoang, HQ Tran, DM Tran, CQ Pham, TD Pham, TV Ha and NT Bui (2011). "Dimethyl sulfoxide-sodium bicarbonate infusion for palliative care and pain relief in patients with metastatic prostate cancer." Journal of pain & palliative care pharmacotherapy 25 (4):350-355 . [Non-Patent Literature 17] Hoang, BX, SA Levine, DG Shaw, P. Pham and C. Hoang (2006). "Bronchial epilepsy or broncho-pulmonary hyper-excitability as a model of asthma pathogenesis." Medical hypotheses 67 ( 5): 1042-1051. [Non-Patent Literature 18] Hoang, BX, DG Shaw, S. Levine, C. Hoang and P. Pham (2007). "New approach in asthma treatment using excitatory modulator." Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evalua tion of Natural Product Derivatives 21 (6):554-557. [Non-Patent Literature 19] Hoang, BX, G. Shaw, P. Pham and SA Levine (2010). "Lactobacillus rhamnosus cell lysate in the management of resistant childhood atopic eczema." Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy) 9 (3): 192-196. [Non-Patent Document 20] Hoang, BX, DM Tran, HQ Tran, PT Nguyen, TD Pham, HV Dang, TV Ha, HD Tran, C. Hoang and KN Luong (2011). "Dimethyl sulfoxide and sodium bicarbonate in the treatment of refractory cancer pain." Journal of pain & palliative care pharmacotherapy 25 (1): 19-24. [Non-Patent Document 21] X Hoang, B., S. A Levine, D. G Shaw, D. M Tran, H. Q Tran, P. MT Nguyen, H. D Tran, C. Hoang and P. T Pham (2010). "Dimethyl sulfoxide as an excitatory modulator and its possible role in cancer pain management." Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy) 9 (4): 306-312. [Non-patent literature 22] X Hoang, B., D. Graeme Shaw, P. Pham and S. A Levine (2010). "Treating asthma as an euroelectrical disorder." Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy) 9 (2):130-134.

[The problem to be solved by the invention]

The present invention relates to the field of medicine, in particular to compositions comprising an iodine source and a sulfur source for the treatment and prevention of chronic and acute viral infections and sepsis in humans and animals, for example, iodine as a treatment for these symptoms and dimethyl sulfite composition.

Specifically, the present invention is to provide a composition or medicine for the treatment of COVID-19, and to show an antiviral effect superior to that of the conventionally known I ₂ or DMSO, which is mainly used for the treatment of chronic or chronic diseases in humans. Medicine for acute viral infection and/or sepsis. [Means for solving problems]

The present inventors completed the present invention by finding that chronic or acute viral infection and/or sepsis in humans or animals can be treated by using a specific iodine source and a specific sulfur source in combination.

That is, the present invention is as described below. [1] A composition for the prevention or treatment of chronic or acute viral infection and/or sepsis in humans or animals, comprising a substance that generates iodine ions and povidone-iodine from dissolving and/or casting in water At least one iodine source selected from the group, and at least one sulfur source selected from the group consisting of dimethylsulfoxide and methylsulfonylmethane. [2] A composition for the prevention or treatment of chronic or acute viral infection and/or sepsis in humans or animals, comprising at least one iodine source selected from the group consisting of iodide salts and povidone-iodine, and at least one sulfur source selected from the group consisting of dimethylsulfoxide and methylsulfonylmethane. [3] A composition for the prevention or treatment of chronic or acute viral infection and/or sepsis in humans or animals, comprising at least one iodine source selected from the group consisting of iodide salts and povidone-iodine, It is characterized by being used in combination with at least one sulfur source selected from the group consisting of dimethylsulfoxide and methylsulfonylmethane. [4] A composition for the prevention or treatment of chronic or acute viral infection and/or sepsis in humans or animals, comprising at least 1 selected from the group consisting of dimethylsulfoxide and methylsulfonylmethane A sulfur source characterized by being used in combination with at least one iodine source selected from the group consisting of iodide salts and povidone-iodine. [5] The composition according to any one of [1] to [4], wherein the sulfur source is combined with the iodine source to improve the therapeutic effect of the sulfur source. [6] The composition according to any one of [1] to [5], wherein the dosage of the aforementioned iodine source and the aforementioned sulfur source per 1 kg of the body weight of a human or animal per day is determined by the aforementioned iodine source. The sulfur atom contained in the sulfur source is in a ratio of 20 mol or more and 200 mol or less per 1 mol of the contained iodine atom. [7] The composition according to any one of [1] to [6], wherein the amount of the aforementioned iodine source per 1 kg of human or animal body weight is 1 mass part, and the aforementioned sulfur source per 1 mass When the above-mentioned iodine source is an iodide salt, the dosage per 1 kilogram of the body weight of a human or animal is 5 parts by mass or more and 100 parts by mass or less, and when the above-mentioned iodine source is pravidone-iodine, it is 5 parts by mass or more and 100 parts by mass. parts by mass or less. [8] The composition according to any one of [1] to [7], wherein the dosage of the aforementioned iodine source per 1 kg of the body weight of a human or animal per day is when the aforementioned iodine source is an iodide salt. 0.5 mg to 10 mg, when the aforementioned iodine source is pravidone-iodine, 0.5 mg to 50 mg, and the aforementioned sulfur source is 10 to 1000 mg per 1 kg of human or animal body weight per day. [9] The composition according to any one of [1] to [8], wherein the dosage of the aforementioned iodine source per 1 kg of the body weight of humans or animals per day is when the aforementioned iodine source is an iodide salt, which is 1 mg to 5 mg, when the aforementioned iodine source is pravidone-iodine, it is 1 mg to 40 mg, and the dosage of the aforementioned sulfur source per 1 kg of human or animal body weight is 100 to 500 mg. [10] The composition according to any one of [1] to [9], wherein the iodine source is an iodide salt, the iodide salt is a metal salt other than zinc iodide (ZnI ₂ ), and the metal salt is simultaneously Zinc salts other than zinc iodide are used, and the iodide salt of metal salts other than the aforementioned zinc iodide is 2 to 20 parts by mass with respect to 1 part by mass of the zinc salts other than the aforementioned zinc iodide. [11] The composition according to any one of [1] to [9], wherein the iodine source is an iodide salt, the iodide salt is a metal salt other than zinc iodide (ZnI ₂ ), and the metal salt is simultaneously Zinc salts other than zinc iodide are used, and the iodide salt of metal salts other than the aforementioned zinc iodide is 3 to 10 parts by mass relative to 1 part by mass of the zinc salts other than the aforementioned zinc iodide. [12] The composition according to any one of [1] to [11], wherein the iodine source is an iodide salt, and the iodide salt is selected from ZnI ₂ , CuI ₂ , FeI ₂ , NaI, Ga ₂ I ₆ and at least one selected from the group formed by KI. [13] The composition according to any one of [1] to [12], wherein the iodine source is an iodide salt, the iodide salt is a metal salt other than zinc iodide (ZnI ₂ ), and iodide is used simultaneously Zinc salts other than zinc. [14] The composition of [13], wherein the aforementioned iodide salt is at least one selected from the group consisting of CuI ₂ , FeI ₂ , NaI, Ga ₂ I ₆ and KI, and zinc acetate ((CH ₃ COO) ₂ Zn). [15] The composition according to any one of [1] to [14], which is a group consisting of oral, parenteral, rectal, nasal spray, oral spray, transdermal, drip and aerosol spray A pharmaceutically acceptable dosage form of at least one selected from the group. [16] The composition according to any one of [1] to [15], which is used for the prevention or treatment of COVID-19. [17] The composition according to any one of [1] to [16], which comprises iodine and dimethylsulfoxide for the prevention and treatment of chronic and acute viral infections and septicemia in humans and animals. [18] A therapeutic composition for the prevention and treatment of chronic and acute viral infections and sepsis in humans and animals, comprising iodine and dimethylsulfoxide. [19] The therapeutic composition according to [17] or [18], wherein the dimethylsulfite is combined with an iodine compound to enhance the therapeutic effect of dimethylsene. The term iodine is meant to include molecular iodine ( _I2 ), iodide salts ( _ZnI2 , _CuI2 , NaI or KI), iodate (NaIO), and/or iodotyrosine or iodolactone or methionine - any form of lipid or protein molecule containing iodine (iodine group) moiety, such as iodine, povidone-iodine, iodine acetate, etc. [20] The dosage of the ingredients in the therapeutic composition according to any one of [17] to] 19] is: Zinc iodide: 0.5 mg to 10 mg per 1 kg of body weight, preferably 0.5 mg to 10 mg per 1 kg of body weight 1 to 5 mg, a mixture of zinc salt and iodide is used in a ratio of 2 to 20 parts of iodide to 1 part of zinc salt, preferably 3 to 10 parts of iodide to 1 part of zinc salt (eg: 1 part of zinc acetate and 5 parts of potassium iodide, or 1 part of zinc acetate and 5 parts of sodium iodide), molecular iodine (I ₂ ) or derivatives: 0.05 mg to 10 mg per 1 kg of body weight, dimethyl sulfoxide ( DMSO): 10 to 1000 mg per 1 kg of body weight, preferably 100 to 500 mg per 1 kg of body weight. [21] The therapeutic composition according to any one of [17] to [20], which is a pharmaceutical preparation via oral, parenteral, rectal, nasal and oral sprays, transdermal or drip or aerosol sprays The application of the above tolerable formulations is used for the prevention and treatment of acute and chronic viral infections in humans and animals. [22] A preparation for constituting the composition of any one of [1] to [21], which is formed from at least one iodine source selected from the group consisting of an iodide salt and povidone-iodine . [23] A preparation for constituting the composition of any one of [1] to [21], which is at least one sulfur selected from the group consisting of dimethylsulfoxide and methylsulfonylmethane formed by the source. [24] A method for the prevention or treatment of chronic or acute viral infection and/or sepsis, comprising administering the composition of any one of [1] to [21] to a human or animal. [Effect of invention]

According to the present invention, it is possible to provide compositions and medicines for the treatment of COVID-19, as well as antiviral effects that are superior to those of conventional I ₂ or DMSO, which are mainly used for the treatment of chronic or acute human diseases. Medications for viral infections and/or sepsis.

In particular, the combination of treatments of the present invention has a broad range of virucidal effects on viruses containing DNA and RNA. In addition to the virucidal effect, the therapeutic composition of the present invention also exhibits anti-inflammatory, immunomodulatory and antioxidant effects. The composition of the present invention can be used as an effective and safe aseptic and disinfectant for humans and animals.

Hereinafter, the embodiments of the present invention will be described in detail, but the present invention is not limited to those of the following embodiments, and may be implemented by adding appropriate changes within the scope of the object of the present invention.

<Composition for prevention or treatment of viral infection and/or sepsis> The first aspect of the present invention is a composition for the prevention or treatment of viral infection and/or sepsis. The composition may be a composition for the prevention or treatment of chronic or acute viral infection and/or sepsis in humans or animals, preferably for the prevention or treatment of chronic or acute viral infection and/or sepsis in humans The composition, more preferably a composition for the treatment of chronic or acute viral infection and/or sepsis in humans.

A first aspect of the present invention is characterized in that a specific iodine source and a specific sulfur source are used in combination. The specific iodine source is at least one selected from the group consisting of substances that generate iodine ions after being dissolved and/or administered in water, and povidone-iodine.

The substance that generates iodide ions by dissolving in water should just be one that can generate iodide ions when mixed with a medium containing water. Here, the "medium containing water" may be only water, or may be a medium containing not only water but components other than water, and typically, it may be a liquid dosage form, for example, liquid preparations, injections, drips, gas Sol, nasal spray, oral spray, spray, etc., and also can be solids such as powders (powders), granules, lozenges, capsules, pills, etc., when they are sold or provided, and mixed in an aqueous medium when administered. dosage form.

Substances that generate iodine ions after administration include, for example, those that can generate iodine ions after administration to humans or animals, and specifically, body fluids (existing in blood, lymph, digestion, etc.) in vivo after administration to a living body. fluid, tissue fluid, liquids such as cells, tissues, or organs, water in the living body, etc.), or the water in the living body derived from food and drink, which can generate iodide ions.

The specific iodine source is a substance that generates iodide ions by dissolving in water, and may also be a substance that generates iodine ions after administration. The substance that generates iodide ions by dissolving and/or administration in water is typically an iodide salt, and examples of the iodide salt include those described later. Povidone-iodine also has the potential to generate iodide ions upon dissolution and/or administration in water.

Furthermore, the specific iodine source may also be at least one selected from the group consisting of iodide salt and povidone-iodine. Here, although the iodide salt and povidone-iodine may not be substances that generate iodide ions after being dissolved in water and/or administered, they preferably have the possibility of generating iodide ions after being dissolved and/or administered in water. sex.

Examples of the iodide salt include metal salts of iodine, preferably at least one selected from the group consisting of ZnI ₂ , CuI ₂ , FeI ₂ , NaI, gallium iodide (Ga ₂ I ₆ ) and KI, more preferably It is at least one selected from the group consisting of ZnI ₂ , NaI and KI, and more preferably at least one selected from the group consisting of ZnI ₂ and NaI.

In the first aspect of the present invention, a specific iodine source, a specific sulfur source, and a further zinc source are preferably combined. The zinc source is a substance that supplies zinc elements (including zinc atoms and zinc ions). As a zinc source, the thing which produces|generates zinc ion by dissolving in water and/or administration is mentioned. Here, substances that generate zinc ions after dissolving and/or administration in water can be replaced by "iodine ions" in the above description of "substances that generate iodine ions after dissolving and/or administration in water" It is "zinc ion".

Typical examples of zinc sources or substances that generate zinc ions by dissolving and/or administration in water include zinc salts, preferably anions with no or low possibility of adversely affecting the living body, or substances capable of generating anions Salts of (elements, atoms, compounds) and zinc, more preferably zinc iodide (ZnI ₂ ), salts of carboxylic acids such as acetic acid, and zinc, still more preferably zinc iodide, zinc acetate ((CH ₃ COO) ₂ Zn ). Since zinc iodide is the above-mentioned specific iodine source and is also a zinc source, it can be used as both of them. Therefore, as a specific iodine source and a zinc source, zinc iodide can be used.

When the iodide salt is a metal salt other than zinc iodide (ZnI ₂ ), it is preferable to use a zinc salt other than zinc iodide together. For example, when the iodide salt is at least one selected from the group consisting of CuI ₂ , FeI ₂ , NaI, Ga ₂ I ₆ and KI, zinc acetate ((CH ₃ COO) ₂ Zn) is preferably used together. Specifically, the combination of CuI ₂ and zinc acetate, the combination of FeI ₂ and zinc acetate, the combination of NaI and zinc acetate, the combination of Ga ₂ I ₆ and zinc acetate, the combination of KI and zinc acetate, preferably NaI The combination with zinc acetate or the combination of KI and zinc acetate is more preferably the combination of NaI and zinc acetate.

In this specification, an iodine element or an iodide ion (iodide ion; I ⁻ ) may be simply referred to as “iodine”, and an iodide ion (I ⁻ ) is also referred to as an “iodine ion”. In addition, in this specification, "zinc salt", specifically, also abbreviate|omits to refer to the zinc salt other than zinc iodide ( _ZnI2 ).

The specific sulfur source is at least one selected from the group consisting of dimethylsulfoxide (DMSO) and methylsulfonylmethane (MSM). Can be either DMSO only or MSM, preferably DMSO. In addition, the description of DMSO in this specification can also be applied to MSM.

The composition of this aspect uses a specific iodine source and a specific sulfur source in combination as a pharmacologically active ingredient (pharmaceutical ingredient, active agent), and typically contains iodine (iodine element, iodide ion) and dimethylsulfite . It is believed that a specific sulfur source in combination with a specific iodine source enhances the therapeutic effect of that sulfur source.

How a specific iodine source and a specific sulfur source achieve functional effects, although the mechanism of action is not yet clear, it is believed that a specific iodine source or a part of it, or the iodine element or iodide ions generated from the iodine source, and the specific sulfur source at the same time. The possibility of action, the possibility of producing iodine ions from a specific iodine source (for example, the possibility of achieving an antiviral effect), the specific sulfur source being a stabilizer and/or iodine ion, iodine element or iodine source Furthermore, even if any adverse effects (side effects, etc.) are assumed due to iodide ions, iodine elements, or iodine sources, there is a possibility that a specific sulfur source can protect the living body from such adverse effects. For example, when a sufficient therapeutic effect is obtained by zinc iodide, even if it is assumed that the iodide ion or iodine element has any adverse effects (side effects, etc.), it is considered that a specific sulfur source such as DMSO may protect the living body from such adverse effects. .

For the prevention and treatment of viral infection or sepsis, in the current treatment plan, typically, a combination of zinc iodide (ZnI ₂ ), or a mixture of zinc salt and iodide salt (preferably zinc acetate and potassium iodide or iodine) sodium chloride), iodine crystals, or iodine derivatives (specifically, puvidone-iodine (also known as betadine, povidone-iodine), methionine-iodine, iodine acetate, etc.) and dimethylsulfoxide Dust (DMSO) is used. Therapeutic composition combining the aforementioned two components, namely, ZnI ₂ or zinc salt/iodide salt or iodine or iodine derivative and DMSO, in the suppression, prevention and treatment of symptoms of all kinds of viral infections and sepsis , showing a strong synergistic effect.

Examples of viral infections for which the composition of this aspect is effective include infections caused by SARS-COV-2, COVID-19 (for example, cases 8 and 9 to be described later), viral pneumonia (for example, case 1 to be described later), Influenza such as influenza A (for example, case 7 described below), respiratory virus infections with unspecified viruses of common colds (for example, cases 2, 3, and 6 described below), genital herpes virus (for example, case 4 described later), herpes In addition to viral infections (which may be possible in case 5 described later), hepatitis B, hepatitis C, HIV infection, RSV infection, human papillomavirus infection (HPV), and the like.

Viral infections and/or septicemia for which the composition of the present invention is effective can also be associated with dry cough, severe dry cough, sore throat, sneezing (severe sneezing, etc.), chest and nose congestion, headache, and chest pain (chest pain). ), muscle pain, body pain, shortness of breath, dyspnea, respiratory failure (acute respiratory failure, etc.), respiratory function limitation, acute bronchitis, fatigue (extreme fatigue, etc.), fatigue, chills, pneumonia (inflammatory reaction, etc.) . Lower lobe pneumonia on both sides, etc.), chest congestion, pleural effusion, abdominal swelling, abdominal pain, heart failure, rapid heartbeat such as heart rate 114 to 115 per minute, breath rate such as 32 to 36 breaths per minute, 72 to 86% Oxygen saturation (SpO ₂ : 72%, 75%, 86%, etc.), around 38 to 40°C (including 38°C, 38.7°C, 39°C, 39.5°C, etc.), fever, liver disease, liver enzymes and blood lactic acid (lactate) increase, serum creatine increase, thrombocytopenia, leukopenia, congestive heart failure, second-stage renal failure, hypotension, type II insulin-dependent diabetes, acute burning pain, vulvar blisters, Those with symptoms or conditions such as painful blisters, blisters, watery discharge, rectal cancer, loss of appetite, hemorrhagic diarrhea (mixed with blood diarrhea), and anosmia accompanied by painful blisters on both sides of the face or in the mouth.

Patients with viral infections and/or septicemia in which the composition of the present invention can show effects include lung cancer, breast cancer, prostate cancer, prostate cancer with metastases to bones, lungs, lymph nodes, etc., gastritis, gastric ulcer, chronic active disease, etc. Patients with a history of hepatitis B, Crohn's disease, asthma, COPD (chronic obstructive pulmonary disease), etc., with a history of smoking, etc.

The composition of this aspect is considered to also have antiviral, anti-inflammatory, antifungal, antibacterial, immunomodulatory, antifibrotic, antithrombotic, cardiac and respiratory assisting activities, etc., and by virtue of these activities, patients or animals can also be relieved of these symptoms.

The composition of this aspect, even with penem, vancomycin, Solu-Medrol, paracetamol, dexamethasone, Tamiflu, acyclovir, corticosteroids, etc. Administration of antibiotics, cough suppressants, bronchodilators, antipyretics, Ringer-lactate solution, nutritional supplements, Chinese herbal medicines, other antiviral drugs and other drugs, and oxygen therapy Symptoms (patients, etc.), or those conditions that do not improve symptoms after such treatments (patients, etc.), can also alleviate these symptoms in patients or animals.

The dosage of a specific iodine source and a specific sulfur source per 1 kg of body weight of humans or animals per day, as the ratio of iodine atoms contained in the iodine source per 1 mole of sulfur atoms contained in the sulfur source For example, 20 mol% or more and 200 mol% or less can be cited. As the lower limit, preferably 25 mol% or more, more preferably 30 mol% or more, and as the upper limit, preferably 180 mol% % or less, more preferably 30 mol % or less.

For a specific iodine source, the dosage per 1 kg of human or animal body weight per day is 1 mass part, and the specific sulfur source is the dosage per 1 kg of human or animal body weight per day. Specific iodine sources can be listed. In the case of an iodide salt, for example, in the range of 5 parts by mass or more and 100 parts by mass or less, the lower limit is preferably 10 parts by mass or more, more preferably 20 parts by mass or more, and the upper limit is preferably 90 parts by mass parts by mass or less, more preferably 80 parts by mass or less.

For a specific iodine source, the dosage per 1 kg of human or animal body weight per day is 1 mass part, and the specific sulfur source is the dosage per 1 kg of human or animal body weight per day. Specific iodine sources can be listed. When it is povidone-iodine, for example, in the range of 5 parts by mass or more and less than 100 parts by mass, as the lower limit, preferably 10 parts by mass or more, more preferably 20 parts by mass or more, as the upper limit, preferably 90 parts by mass or less, more preferably 80 parts by mass or less.

The dosage per 1 kg of human or animal body weight per 1 day of a specific iodine source is as follows. (1) When the specific iodine source is an iodide salt, for example, the range of 0.5 mg to 10 mg can be cited. As the lower limit, preferably 1 mg or more, more preferably 2 mg or more, and as the upper limit, preferably It is 7 mg or less, more preferably 5 mg or less. (1-1) The specific iodine source is an iodide salt, and the iodide salt is a metal salt other than zinc iodide (ZnI ₂ ), and when a zinc salt other than zinc iodide is used as the metal salt, the zinc iodide 1 mole of zinc salt other than zinc iodide, the iodide salt of metal salt other than zinc iodide, for example, in a ratio of 2 to 5 moles, and further, for 1 mass part of zinc salt other than zinc iodide, the iodide salt The iodide salt of metal salts other than zinc can be, for example, in the range of 1 to 20 parts by mass, and the lower limit is preferably 2 parts by mass or more, more preferably 3 parts by mass or more, and the upper limit is preferably It is 10 mass parts or less, More preferably, it is 5 mass parts or less. (2) When the specific iodine source is pravidone-iodine, for example, the range of 0.5 mg to 50 mg can be listed, as the lower limit, preferably 1 mg or more, more preferably 2 mg or more, as the upper limit, Preferably it is 40 mg or less, more preferably 30 mg or less.

The dosage of a specific sulfur source per 1 kg of human or animal body weight per day, for example, can be listed in the range of 10 to 1000 grams (10 to 1000 milliliters), as the lower limit, preferably 100 grams (100 milliliters) ) or more, more preferably 200 g (200 ml) or more, and the upper limit is preferably 700 g (700 ml) or less, more preferably 500 g (500 ml) or less. These amounts are particularly suitable for DMSO. DMSO may be replaced with methylsulfonylmethane (MSM), and in this case, the dosage is preferably 10 mg to 150 mg (10 ml to 150 ml) per 1 kg of body weight per day.

The dosage of the present therapeutic composition The dosage of the present therapeutic composition is preferably as follows, for example. Zinc iodide: 0.5 to 10 mg per 1 kg body weight, preferably 1 to 5 mg per 1 kg body weight of a mixture of zinc salt and iodide, can be 2 to 20 parts of iodide salt for 1 part of zinc salt, more It is preferable to use the ratio of 3 to 10 parts of iodide salt to 1 part of zinc salt (for example: 1 part of zinc acetate and 5 parts of potassium iodide, or 1 part of zinc acetate and 5 parts of sodium iodide) Molecular iodine (molecular iodine: I ₂ ) or derivatives: 0.05 to 10 mg per 1 kg body weight of dimethylsulfoxide (DMSO): 10 to 1000 mg (10 to 1000 ml) per 1 kg body weight, preferably 100 mg per 1 kg body weight to 500 mg (100 to 500 mL).

Examples of dosage forms of the composition of this aspect include oral liquids, soft gels, suspensions, aerosols, gels, oral ointments, transdermal agents, and sprays such as nasal and oral sprays. Eye drops or ear drops, parenterals, rectal suppositories (suppositories), drips, intramuscular injections, intravenous injections and other injections, powders, powders, granules, lozenges, capsules, pills, liquids, etc.

The composition of this aspect may contain other components within the range that does not impair the intended effect. As other components, for example, sweeteners, flavors (correctives), excipients, bases, emulsifiers, solvents (for example, water), stabilizers, pH adjusters, and the like can be exemplified.

The composition of this aspect may be a composition that combines a specific iodine source, a specific sulfur source, and a further zinc source according to the situation at the time of sale, etc., or may be provided at the time of sale, etc., At least one selected from the group consisting of a specific iodine source, a specific sulfur source, and an arbitrary zinc source is prepared separately (as a separate preparation or composition), and mixed in clinical situations such as administration.

As an administration method of the composition of this aspect, for example, oral administration, nasal administration, spray administration, transdermal administration, eye instillation, ear instillation, instillation (via installation) can be mentioned. , intramuscular injection, intravenous injection, intraperitoneal injection, rectal suppository, etc., enteral administration, etc., preferably oral administration, nasal administration, spray administration, intravenous administration. For example, in the case of oral administration, it can be administered once to several times a day (for example, twice or three times).

The administration period of the composition of this aspect is preferably until the symptoms of viral infection and/or sepsis are relieved or cured, for example, 1 hour to 24 hours after the initial administration, for example, 1 hour to 12 hours can be observed. , 1 hour to 6 hours, 1 hour to 3 hours, 1 hour to 2 hours, the relief of short-term fever (hyperthermia), the relief of pain and other symptoms are relieved. For better symptom alleviation, the administration of the composition of this aspect can be continued for more than 1 day, for example, preferably more than 2 days, more preferably more than 3 days. Although there is no particular limitation on the upper limit of the number of days of continuous administration, for example, one month (within 30 to 31 days) may be mentioned, for example, within 15 days, within 12 days, within 10 days, or within 5 days. within 3 days.

<Preparation for forming the composition of the first aspect from a specific iodine source> The second aspect of the present invention is a preparation for constituting the composition of the first aspect, which is formed from at least one iodine source selected from the group consisting of iodide salts and povidone-iodine.

The preparation of the second aspect is used to constitute, prepare or manufacture the composition of the first aspect, and contains a specific iodine source. As the preparation, for example, it can be prepared as a preparation or composition separately or separately from the preparation or composition containing a specific sulfur source and an arbitrary zinc source at a time point provided by sales, an offer for sales, etc., Manufactured or supplied, and mixed in clinical situations such as administration to humans or animals, and can also be used for composition, preparation or manufacture including specific The single composition of the first aspect of the iodine source, the specific sulfur source and the arbitrary zinc source. Within the scope of this meaning, the above-mentioned matters about the first aspect also apply to the second aspect.

<Preparation for forming the composition of the first aspect from a specific sulfur source> The third aspect of the present invention is a preparation for constituting the first aspect, which is formed from at least one sulfur source selected from the group consisting of dimethylsulfoxide and methylsulfonylmethane.

The preparation of the third aspect is a preparation for composing, preparing or manufacturing the composition of the first aspect, and containing a specific sulfur source. As the preparation, for example, it can be prepared as a preparation or composition separately or separately from the preparation or composition containing a specific iodine source and an arbitrary zinc source at a time point provided by sales, an offer for sales, etc., Manufactured or supplied, and mixed in clinical situations such as administration to humans or animals, and can also be used for composition, preparation or manufacture including specific The single composition of the first aspect of the iodine source, the specific sulfur source and the arbitrary zinc source. Within the scope of this meaning, the above-mentioned matters about the first aspect also apply to the third aspect.

<Example of prescription> Prescription Example 1 Compositions for oral administration may be formulated as shown below: 5 g (5000 mg) of zinc iodide (or 5 g of zinc acetate and 25 g of potassium iodide or 1 part of zinc acetate and 3 to 15 parts (e.g., 3 or more parts, 5 parts) of 99.4% to 99.9% purity or 5 parts or more, 10 parts or less, 15 parts or less) of sodium iodide or potassium iodide) mixed with 1000 ml of 99.8% dimethyl sulfite solution. (Composition ZnDM-O)

Prescription Example 2 Compositions for intravenous administration may be formulated as follows: 99.8% to 99.9% pure zinc iodide 5g (5000mg) (or 99.8% zinc acetate 5g and 99.8% sodium iodide 25g) mixed with 1000ml of dimethylsulfoxide 99.9% pharmaceutical grade solution . (Composition ZnDM-IV)

Prescription Example 3 Compositions for oral administration may be formulated as follows: 1000 to 5000 mg of povidone-iodine, 50 ml of water for injection and 50 ml of DMSO (Composition PVI-DM) Prescription Example 3-1 Compositions for oral administration may be formulated as follows: Iodine crystal 5000mg (or puvidone-iodine or methionine-iodine), 50ml water for injection and 50ml DMSO (Composition PVI-DM-1)

Prescription Example 4 The composition for nasal and oral nebulizers can be prescribed as follows: Zinc iodide: 2000 mg, DMSO pharmaceutical grade (98.8 to 99.9%): 150 ml, water 900 ml (Composition ZnDM-SP)

Prescription Example 5 Compositions for aerosol or via spray can be formulated as follows: Zinc iodide 1000 to 2000 mg, DMSO pharmaceutical grade (98.8 to 99.8%) 200 ml and water for injection 800 ml (Composition ZnDM-AN)

Prescription Example 6 Compositions for oral administration may be prescribed as follows: 1 part of zinc iodide may be admixed (mixed) with 5 to 50 parts, eg, 5 to 10 parts, of methylsulfonylmethane (MSM). The mixture is formulated into capsules or lozenges with a total weight of 200 to 1000 mg, eg, 300 to 500 mg. The daily dose is 1 to 3 capsules, and the treatment for viral infection or sepsis including SARS-CoV-2 (COVID-19) is 3 times a day. [Example]

Hereinafter, the embodiments are disclosed to specifically illustrate the details of the present invention, but the present invention is not limited to these.

<Examples of preparation of compositions of various dosage forms> Example 1 The composition for oral administration is prescribed as shown below. 5 g (5000 mg) of zinc acetate and 15 g (15000 mg) of sodium iodide were mixed with 100 ml of a 99.8% pure dimethylsulfite solution (composition ZnDM-O).

Example 2 Compositions for intravenous administration are prescribed as shown below. 5 g of 99.8% pure zinc acetate and 25 g of 99.8% pure sodium iodide were mixed with 1000 ml of 99.9% pure pharmaceutical grade dimethylsulfite solution (composition ZnDM-IV).

Example 3 The composition for oral administration was mixed and prepared according to the following recipe. 3750 mg of povidone-iodine, 50 ml of water for injection and 50 ml of DMSO (composition PVI-DM). The daily dose is 2 mg of povidone-iodine per 1 kg of the patient's body weight (or 150 mg for adult patients).

Example 4 The composition for nasal and oral nebulizers was mixed and prepared according to the following prescription. Zinc iodide: 2000 mg, pharmaceutical grade of DMSO (purity 98.8 to 99.9%): 150 ml, water 900 ml (composition ZnDM-SP)

Example 5 Mix and prepare the composition for aerosol or spray according to the following recipe. Zinc iodide 2000 mg, DMSO pharmaceutical grade (purity 98.8 to 99.8%) 200 ml and water for injection 800 ml (composition ZnDM-An) ZnDM-AN was administered in an amount of 10 mg of zinc iodide per dose, or 40 mg of zinc iodide per day.

Example 6: The composition for oral administration can be prepared by the following recipe. 1 part of zinc iodide may be admixed (mixed) with 5 to 50 parts, eg, 5 to 10 parts, of methylsulfonylmethane (MSM). The mixture is formulated into capsules or lozenges with a total weight of 200 to 1000 mg, eg, 300 to 500 mg. The daily dose is 1 to 3 capsules, and the treatment for viral infection or sepsis including SARS-CoV-2 (COVID-19) is 3 times a day.

<Clinical case of treatment of viral infection and/or sepsis> Case 1 A 65-year-old man with a history of lung cancer was admitted to the hospital complaining of dry cough, sneezing, headache, chest pain, muscle pain, and dyspnea. The patient had a heart rate of 115 tachycardia per minute, a respiratory rate of 36 breaths per minute, an oxygen saturation of 86% on oxygen therapy, and exhibited a fever of 38 to 39°C for the past 3 days. Although the patient took antibiotics (penem and vancomycin), antitussives, and antipyretics for the past 3 days, the patient's state and symptoms did not improve.

On a chest X-ray, pneumonia on the right side and pleural effusion on the left and right sides of the lung were confirmed. Even though the patient's white blood cell count was normal on admission, he was still treated with penem and vancomycin, 20 mg of dexamethasone and gram influenza were administered orally daily. After 24 hours, the patient's general state and symptoms did not improve. The patient's liver enzymes and blood lactate (lactate) levels increased, and serum creatine increased. The patient had concurrent thrombocytopenia and leukopenia. The patient was diagnosed with viral pneumonia, and was diagnosed with a status with the possibility of sepsis. The patient's fever was 39.5°C 3 hours after the intravenous infusion of 1000 mg of acetaminophen.

The patient was injected with 20 ml of the composition ZnDM-IV mixed with 500 ml of sodium chloride 0.9%, and the treatment was started at a rate of 50 drops per minute. Five hours after infusion, the patient's fever was reduced to 37.6°C without antipyretic. After that, the patient discontinued antibiotic therapy, dexamethasone, gram influenza, followed by 15 ml of ZnDM-IV solution mixed with 500 ml of sodium chloride every 12 hours for a 4-day period. The patient's symptoms improved significantly 48 hours after treatment, and cough, chest pain, dyspnea, and fatigue were reduced by more than 50%. The patient's fever was completely controlled by 72 hours.

The patient was further treated with 20 mL of ZnDM-IV mixed with 500 mL of 0.9% sodium chloride every 24 hours for 10 days. During the treatment period with this ZnDM-IV, the patient's symptoms continued to improve, and the systemic state also improved.

In the chest X-ray examination after 15 days of ZnDM-IV treatment, the pneumonia on the left side was reduced by more than 80%, and the hydrothorax on both sides was reduced by 60%. The white blood cell count and blood lactate values were within the normal range. The patient's thrombocytopenia, liver enzymes, and creatine were all reduced compared to the data before ZnDM-IV treatment.

Case 2 A 43-year-old man with a fever of 38.5°C showed dyspnea, muscle pain, dry cough, and severe sneezing. The patient's symptoms started 12 hours earlier and had significantly worsened. The patient had a history of gastritis, gastric ulcer, and chronic active hepatitis B. The patient had been taking antiviral drugs for the past 2 years. Due to the patient's liver disease, the patient was unable to take antipyretics for the current symptoms. The patient was diagnosed with a respiratory viral infection and started treatment with 5 ml of ZnDM-O mixed with 150 ml of water every 8 hours. After 6 hours of treatment with ZnDM-O, all symptoms associated with the current disorder were greatly improved, and the fever in patients without antipyretic therapy was reduced to 37.6°C. The patient took ZnDM-O 5 ml three times a day for a period of 6 days. Symptoms in patients associated with respiratory virus were fully controlled within 72 hours. The patient's health status was normalized 5 days from the start of treatment with ZnDM-O.

Case 3 An 82-year-old woman with a history of breast cancer and no specific treatment history showed congestive heart failure, stage II renal failure, hypotension, and type 2 insulin-dependent diabetes. On admission, the patient showed a fever of 39°C, an intense dry cough, sore throat, myalgias, chest and nasal congestion, tachycardia with a heart rate of 114 per minute, and a respiration rate of 32 breaths per minute. Even with previous treatment with a total dose of 3000 mg of acetaminophen, the patient's symptoms did not improve. The patient's blood count was normal, and biological testing showed a marked increase in C-reactive protein of 146 mg/L, SGPT of 121 IU/L, and SGOT of 114 IU/L. On the patient's chest X-ray, there were no signs of pneumonia and no reduction in lung volume was observed.

Patients started treatment with 4 mL of ZnDM-O every 6 hours in 100 mL of water. After 6 hours of treatment, the patient's fever decreased to 37.8°C without antipyretic. The woman's symptoms were relieved, and after 24 hours of treatment with ZnDM-O, the patient's fever decreased to 37.4°C, the heart rate was 98 beats per minute, and the respiration rate was 28 breaths per minute.

The patient continued treatment with ZnDM-O 4 mL mixed with 100 mL of water 3 times a day for the following 9 days. The woman's fever completely recovered within 72 hours of treatment, and the woman's symptoms associated with the current viral infection were significantly reduced by the fifth day of treatment. After 10 days of treatment with ZnDM-O, the patient showed no major symptoms associated with respiratory viral infection.

Case 4 A 51-year-old female complained of acute burning pain due to blisters on the vulva. The patient was diagnosed with genital herpes. During the past 3 days, acyclovir was taken 3 times a day, but the symptoms did not improve significantly, and the size of the vulvar blister was suppressed to a minimum. Patients started treatment with 5 mL of ZnDM-O mixed with 150 mL of water 3 times a day.

After 6 hours from the initial treatment of ZnDM-O, the patient's pain level was reduced by more than 50%. The patient discontinued taking acyclovir and then continued to take 5 ml of ZnDM-O mixed with 150 ml of water three times a day for 9 days. The woman's pain was completely healed on the 3rd day, and the vulvar blister was healed within 6 days after the ZnDM-O treatment.

Case 5 A 76-year-old female presented with pain blisters on both sides of her face and in her mouth, and a fever of 38°C. Even when 400 mg of acyclovir was administered three times a day for 3 days, the number of blisters increased, and secretions appeared on the face and mouth. The patient started the treatment 3 times a day with 5 mL of ZnDM-O mixed with 150 mL of water. The woman's pain levels, which were substantially reduced 6 hours after the start of treatment, were fully controlled by 72 hours. Blisters and watery secretions were significantly reduced 24 hours after treatment with ZnDM-O. The blister healed with treatment during the 12th day.

Case 6 A 74-year-old male patient is suffering from terminal rectal cancer. During the 3 days before admission, he developed symptoms of fatigue, chills, cough, chest pain, and high fever. The patient was diagnosed with respiratory viral infection and acute bronchitis. On admission, the patient's body temperature rose to 39.8°C. After 24 hours of treatment including antibiotic therapy, oxygen therapy, antipyretic therapy, and injection of Ringer-lactate solution, the patient's heat was maintained at a temperature of 39.5°C, and the patient's condition was extreme fatigue and headache. , dyspnea, abdominal swelling, and symptoms of heart failure.

Patients started treatment by oral administration of 1 mL of the PVI-DM composition mixed with 150 mL of water every 6 hours. The patient's condition improved rapidly 2 hours after the start of PVI-DM treatment, and the patient's body temperature decreased to 38.3°C. The patient's symptoms of heart failure and dyspnea gradually improved during the 10-day treatment period. The patient continued oral treatment with 1 mL of PVI-DM mixed with 150 mL of water three times a day without antibiotics for the next 9 days. Symptoms of the patient's pathogenic disease were controlled after 4 days, and the patient's general health status improved significantly. The patient was discharged 11 days later.

Case 7 A 69-year-old man presented with high fever, sore throat, and dry cough for 5 days. The patient was diagnosed with influenza A infection. The patient had a long history of smoking and COPD. The patient has not received specific treatment, and is using nutritional supplements and Chinese herbal medicine to control the patient's COPD symptoms. Patients received antibiotics, an infusion of Solu-Medrol, an oral administration of acetaminophen, a spray of a bronchodilator, and a flu shot. Even with this treatment, the patient's fever and cough persisted 3 days after the start of treatment. On day 4, the patient developed acute respiratory failure with SpO ₂ 87% under a 6 L/min oxygen mask. On chest X-ray, symptoms of pneumonia accompanied by pathogens in expectoration were detected. Patients started treatment with oxygen nebulizers of 5 mL of ZnDM-AN every 4 hours. After 2 times of ZnDM-AN treatment, the patient's fever and cough were significantly improved. SpO ₂ rises to 94% under an oxygen mask at 3 L/min. After 4 times of ZnDM-AN treatment, the patient had no fever, and antipyretic was no longer needed. The dosage of Shu Rumei Zhuoyou was reduced to 50%, and the drug was completely eliminated after 8 days of treatment.

The patient continued the treatment with ZnDM-AN spray four times a day, and was relieved by oxygen therapy and corticosteroids 5 days after the start of treatment. In a chest X-ray after 7 days of treatment, a significant improvement in pneumonia (an inflammatory response) and in the breathing capacity of the lungs was observed. On the 21st day from the start of administration of ZnDM-AN, he was discharged from the hospital with no symptoms of pneumonia and good lung function.

<Example of preparation of composition for treatment of COVID-19 (SARS-COV-2)> Example 7 The composition for oral administration was mixed and prepared according to the following prescription. Zinc iodide 10 g (10,000 mg) 98.0% to 99.8% pure Dimethyl sulfite pharmaceutical grade 98.8% to 99.9% 400ml water 600ml (Composition ZnDM-COVID-O)

Example 8 The composition for intravenous administration can be formulated as follows. Zinc iodide 5 g (5,000 mg) 98.0% to 99.8% pure Dimethyl sulfite pharmaceutical grade 98.8% to 99.9% 600ml 400ml water (Composition ZnDM-COVID-IV)

Example 9 The compositions for nasal and oral sprays and sprays are mixed and prepared according to the following prescriptions. Zinc iodide 2,000 mg 98.0% to 99.8% pure Dimethyl sulfite pharmaceutical grade 98.8% to 99.9% 200ml 800ml water (Composition ZnDM-COVID-SN)

<Clinical case of COVID-19 treatment> Case 8 A 76-year-old man with prostate cancer with metastases to bones, lungs and lymph nodes and a history of moderate smoking over a 51-year period, accompanied by clinical presentation of 38.7°C fever, muscle and lymph nodes. Body pain, intense dry cough with difficulty breathing, sore throat, abdominal pain, extreme fatigue. The patient's symptoms worsened during the 6-day period of presentation, and the RT-PCR test of the nasopharyngeal swab sampling material was positive for COVID-19. The patient underwent X-rays, which revealed bilateral lower lobe pneumonia. The patient's SpO ₂ level was 72% and his pulse rate was 120 per minute. The patient started treatment with bronchodilator inhalation, acetaminophen 1000 mg IV, and 10 mL of ZnDM-COVID-O mixed with 200 mL of water via 6 liters per minute mask oxygen therapy. The patient's condition improved significantly from the initial 2 hours of treatment. The patient's muscle and body pain decreased sharply, SpO ₂ increased by 92% with 3 liters per minute oxygen therapy, pulse rate was 98 per minute, and fever decreased to 36.7°C. The patient received 200 ml of water and 10 ml of ZnDM-COVID-O simultaneously for 6 hours from the initial treatment without other therapeutic drugs. Ten hours after the start of treatment, the patient's pain, breathing pattern, and energy improved, body temperature remained normal, SpO ₂ was 94% without oxygen therapy, and dry cough was reduced by more than 70%. After the first 3 hours of sleep in 3 days, you can eat twice as much as the day before. The patient was treated with 10 mL of ZnDM-COVID-O every 8 hours for the next 48 days. Sustained clinical improvement in all symptoms or symptoms as reported by the patient. 72 hours since the start of treatment, the patient has a normal body temperature, 5 hours of sleep at night, more than 70% improvement in appetite, energy, shortness of breath, no dry cough, body or chest pain associated with prostate cancer experienced before COVID-19 diagnosis also disappeared. The patient's _SpO2 was 95%, and the pulse rate was 86 per minute.

The patient took ZnDM-COVID-O 10 ml three times a day for a further 7 days. From the start of treatment to day 10, the patient's symptoms associated with COVID-19 completely resolved, and the patient's general health status improved significantly. On the 11th day, X-ray examination showed complete resolution of bilateral low lobe pneumonia. The patient further took ZnDM-COVID-O 5 ml three times a day for 5 days, and was discharged on the 16th. COVID-19 testing by RT-PCR of nasopharyngeal swab sampling material on Days 14 and 16 was negative for SARS-CoV-2 RNA.

Case 9 A 54-year-old man with a history of Crohn's disease and asthma, high fever at 39.5°C, complained of severe shortness of breath, dry cough, chest congestion and pain, diarrhea mixed with bleeding, extreme fatigue, body pain and anosmia And to the hospital. Bilateral pneumonia with haze was confirmed on chest X-ray. The patient was diagnosed with suspected COVID-19 7 days ago through close contact with a close relative of a confirmed COVID-19 infection. The patient's _SpO2 was 75%, oxygen therapy was administered at 5 liters per minute via a mask, and the pulse rate was 110 per minute.

Patients were administered 5 mL of ZnDM-COVID-O with 200 mL of water every 6 hours, 5 mL of ZnDM-COVID-SN sprayed every 8 hours, and acetaminophen 1000 mg intravenously by inhalation Bronchodilator, treatment for 72 hours. Four hours after the initial treatment, dry cough, shortness of breath, fatigue, and chest pain were significantly reduced, and the patient's symptoms improved. SpO ₂ reading was 92% on 3 liters per minute oxygen therapy and pulse rate decreased to 92 per minute. The patient's body temperature was 37.2°C. Seventy-two hours from the start of ZnDM-COVID, all symptoms of the patient associated with the current condition improved, and the patient was able to breathe without oxygen therapy and bronchodilator treatment, and without significant shortness of breath or chest pain. The patient's body temperature was in the normal range, SpO ₂ was 96%, and pulse rate was 85 per minute. The patient did not receive nebulization and oxygen therapy during the 12th day, and continued to administer 5 ml of ZnDM-COVID-O every 6 hours. During the 6-day period from the start of treatment, there were no symptoms associated with the current condition and respiratory limitation. The patient's hemorrhagic diarrhea fully recovered from the fourth day of treatment. On the 4th day, the diagnosis of COVID-19 was confirmed in the RT-PCR examination of the nasopharyngeal swab sampling material taken at the time of admission. On the X-ray examination on day 15, no signs of pneumonia were observed. The RT-PCR test of the nasopharyngeal swab sampling material on the 14th and 16th day was negative for SARS-CoV-2 RNA.

without.

without.

Claims (21)

A composition for the prevention or treatment of chronic or acute viral infection and/or sepsis in humans or animals, comprising at least one iodine source selected from the group consisting of iodide salts and povidone-iodine, and two At least one sulfur source selected from the group consisting of methyl sulfoxide and methylsulfonylmethane. A composition for the prevention or treatment of chronic or acute viral infection and/or sepsis in humans or animals, comprising a group consisting of a substance that generates iodine ions after dissolving and/or administering to water and povidone-iodine At least one source of iodine selected from the group, and at least one source of sulfur selected from the group consisting of dimethylsulfoxide and methylsulfonylmethane. The composition according to claim 1 or 2, wherein the sulfur source is combined with the iodine source to improve the therapeutic effect of the sulfur source. The composition according to any one of claims 1 to 3, wherein the amount of the iodine source and the sulfur source per 1 kg of the body weight of a human or animal per day is the amount of iodine contained in the iodine source. The sulfur atom contained in the sulfur source is in a ratio of 20 mol or more and 200 mol or less per atom per mol. The composition according to any one of claims 1 to 4, wherein the dosage of the aforementioned iodine source per 1 kg of human or animal body weight is 1 mass part, and the aforementioned sulfur source per day of human Or the amount per kilogram of the animal's body weight is When the aforementioned iodine source is an iodide salt, it is 5 parts by mass or more and 100 parts by mass or less, When the aforementioned iodine source is pravidone-iodine, it is 5 parts by mass or more and 100 parts by mass or less. The composition according to any one of claims 1 to 4, wherein the amount of the aforementioned iodine source per 1 kg of the body weight of a human or animal per day is When the aforementioned iodine source is an iodide salt, it is 0.5 mg to 10 mg, When the aforementioned iodine source is pravidone-iodine, it is 0.5 mg to 50 mg, The dosage of the aforementioned sulfur source per 1 kg of human or animal body weight is 10 to 1000 mg. The composition according to any one of claims 1 to 5, wherein the dosage of the aforementioned iodine source per 1 kg of the body weight of a human or animal per day is When the aforementioned iodine source is an iodide salt, it is 1 mg to 5 mg, When the aforementioned iodine source is pravidone-iodine, it is 1 mg to 40 mg, The dosage of the aforementioned sulfur source per 1 kg of human or animal body weight is 100 to 500 mg. The composition according to any one of Claims 1 to 7, wherein the iodine source is an iodide salt, and the iodide salt is a metal salt other than zinc iodide (ZnI ₂ ), and the metal salt uses iodide simultaneously Zinc salts other than zinc are 2 to 20 parts by mass of iodide salts of metal salts other than zinc iodide per 1 part by mass of zinc salts other than zinc iodide. The composition according to any one of Claims 1 to 7, wherein the iodine source is an iodide salt, and the iodide salt is a metal salt other than zinc iodide (ZnI ₂ ), and the metal salt uses iodide simultaneously Zinc salts other than zinc are 3 to 10 parts by mass of iodide salts of metal salts other than zinc iodide with respect to 1 part by mass of zinc salts other than zinc iodide. The composition according to any one of claims 1 to 7, wherein the iodine source is an iodide salt, and the iodide salt is selected from ZnI ₂ , CuI ₂ , FeI ₂ , NaI, Ga ₂ I ₆ and KI Make up at least 1 of the group options. The composition according to any one of claims 1 to 7, wherein the iodine source is an iodide salt, the iodide salt is a metal salt other than zinc iodide (ZnI ₂ ), and a metal salt other than zinc iodide is used simultaneously Zinc salts. The composition according to claim 11, wherein the iodide salt is at least one selected from the group consisting of CuI ₂ , FeI ₂ , NaI, Ga ₂ I ₆ and KI, and zinc acetate ((CH ₃ ) is used simultaneously COO) ₂ Zn). The composition of any one of claims 1 to 12, which is selected from the group consisting of oral, parenteral, rectal, nasal spray, oral spray, transdermal, drip and aerosol spray At least one pharmaceutically acceptable dosage form. The composition according to any one of claims 1 to 13, which is used for the prevention or treatment of COVID-19. The composition according to any one of claims 1 to 14, which is used for the prevention and treatment of chronic and acute viral infections and sepsis in humans and animals, comprising iodine and dimethylsulfoxide. A therapeutic composition for the prevention and treatment of chronic and acute viral infections and sepsis in humans and animals, comprising iodine and dimethylsulfoxide. The therapeutic composition according to claim 15 or 16, wherein the dimethyl sulfite is combined with an iodine compound to enhance the therapeutic effect of the dimethyl sulfite; wherein the term iodine means that molecular iodine (I ₂ ) is included. , iodide salt (ZnI ₂ , CuI ₂ , NaI or KI), iodate (NaIO), and/or iodotyrosine or iodolactone or methionine-iodine, pravidone-iodine, iodine acetate Any form of molecules such as lipids or proteins that contain iodine (iodine-based) moieties. The therapeutic composition according to any one of claims 15 to 17, wherein the dosage of the ingredients is: Zinc iodide: 0.5 mg to 10 mg per 1 kg of body weight, preferably 1 to 5 mg per 1 kg of body weight mg, the mixture of zinc salt and iodide is used in a ratio of 2 to 20 parts of iodide to 1 part of zinc salt, preferably 3 to 10 parts of iodide salt to 1 part of zinc salt (eg: zinc acetate 1 part and 5 parts potassium iodide, or 1 part zinc acetate and 5 parts sodium iodide), molecular iodine (I ₂ ) or derivatives: 0.05 mg to 10 mg per 1 kg body weight, dimethylsulfoxide (DMSO) : 10 to 1000 mg per 1 kg of body weight, preferably 100 to 500 mg per 1 kg of body weight. The therapeutic composition according to any one of claims 15 to 18, which is used for the prevention and treatment of acute and chronic viral infections in humans and animals, and the composition is administered orally, parenterally, rectally, Use of pharmaceutically acceptable formulations for nasal and oral sprays, transdermal or spot-on or aerosol sprays. A formulation for constituting the composition of any one of claims 1 to 19, which is formed from at least one iodine source selected from the group consisting of iodide salts and povidone-iodine. A preparation for forming the composition according to any one of claims 1 to 19, which is composed of at least one sulfur source selected from the group consisting of dimethylsulfoxide and methylsulfonylmethane form.